Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Articles / Mar / Total Eradication
Manufacture Vaccines

Total Eradication

Will a new VLP-based polio vaccine help rid the world of the disease once and for all?

By Maryam Mahdi 03/20/2020 1 min read

Share

CPI – a member of the UK government's High Value Manufacturing Catapult – is collaborating with the University of Leeds, UK, to develop a low-cost, scalable manufacturing process for a non-infectious, stable vaccine against polio. Developed using virus-like particles (VLP), the vaccine is intended to improve the safety and accessibility of treatment, particularly in low- and middle-income countries.

Since the introduction of the Global Polio Eradication Initiative in 1988, cases of polio have plummeted by 99 percent – with the oral polio vaccine (OPV) playing a key role in facilitating large-scale immunization. But despite success with OPV, it suffers a number of drawbacks; firstly, the RNA-dependent RNA polymerase enzyme that is responsible for making copies of the PV genomic RNA is error-prone. “In rare cases, use of the OPV can, therefore, cause disease in vaccine recipients or their close contacts. In situations of low vaccine coverage, this can lead to localized outbreaks,” says Natasha Lethbridge, Project Manager, CPI.

Secondly, there is a small number of immune-deficient or immunocompromised people who are unable to clear the virus after vaccination, which means they persistently shed vaccine-derived virus for long periods of time after immunization. Such individuals represent a potential source of infection if they were to stop vaccine use. 

As a result, OPV is being replaced by an inactivated polio vaccine (IPV) in much of the world – but in some regions, IPV may be too expensive.

The new VLP vaccine should be able to overcome both scientific and economic issues. Composed of empty protein shells that mimic PV sufficiently to induce an immune response, the VLP vaccine lacks the genetic material needed for infectivity, overcoming biosafety concerns. “And because the vaccine can be made under low levels of containment, it would also make the product much more affordable than the current IPV offering for low and middle-income countries,” says Lethbridge.

And once scientific and economic issues have been solved? Geopolitics may present the final hurdle. “It can be extremely challenging to vaccinate in remote areas,” according to Lethbridge. “And, in some instances, vaccinators have been targeted by radical groups amidst regional conflicts.”

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Maryam Mahdi

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

More Articles by Maryam Mahdi

False

Advertisement

Recommended

False

Related Content

Understanding the H5N1 Threat
Vaccines Drug Discovery
Understanding the H5N1 Threat

February 3, 2025

4 min read

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Peter Marks Resigns from FDA
Standards & Regulation Profession Vaccines Advanced Medicine
Peter Marks Resigns from FDA

April 1, 2025

3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”

The Shingles Vaccine and Dementia
Drug Discovery Translational Science Vaccines
The Shingles Vaccine and Dementia

April 10, 2025

2 min read

Studies have suggested that the RZV shingles vaccine can lower the risk of dementia; GSK is now investigating further

Robert F. Kennedy Jr Nomination Advances
Standards & Regulation Vaccines
Robert F. Kennedy Jr Nomination Advances

February 6, 2025

2 min read

Senate committee votes in favor of the nomination; full Senate vote will be next

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.